Drug intelligence / Profile preview

OP2102

Development stage: Preclinical
Lead developer: Orchestrate Pharma
Modality: Small Molecules
Administration: Topical

Overview

OP2102 is a topical drug candidate being developed by Orchestrate Pharma as part of its proprietary FexoTopic technology platform. The platform utilizes fexofenadine, a second-generation H1-receptor antagonist, repurposed for localized delivery to the skin to treat inflammatory and allergic conditions. While Orchestrate Pharma has disclosed that its lead candidate, OP2101, is in Phase 1 development for atopic dermatitis, specific clinical details and indications for OP2102 remain proprietary and have not been publicly detailed. The drug is designed to provide localized antihistamine effects with minimal systemic absorption, potentially addressing symptoms such as pruritus and inflammation in various dermatological disorders.

Brand names: FexoTopic TPP

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on OP2102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OP2102.

Explore the full profile